February 22, 2018
Gilead Sciences Announces Senior Management Change
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 22, 2018--
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that James Meyers,
Executive Vice President, Commercial Operations, will retire. Mr. Meyers
joined Gilead in 1996 as a regional sales director and was appointed to
his current role in 2016. Following a brief family leave earlier this
year, Mr. Meyers made the decision to retire from his full-time role
effective immediately. Mr. Meyers will remain with the company in an
advisory capacity, to consult on priority projects and to assist with
identifying his successor and facilitating the transition. The company
will begin a search for his successor in the coming weeks.
“Jim has been instrumental in leading Gilead through a period of
tremendous growth and change, and he has built an exceptional team. I am
confident in the ability of that team to execute against our ambitious
goals and grateful to Jim for his commitment to assist us through this
transition,” said John Milligan, PhD, President and Chief Executive
Officer, Gilead Sciences. “We wish Jim the very best, and thank him for
his many contributions to Gilead over the last 22 years.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222006545/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792